Acute Myeloid Leukemia Excellence Forum

Acute Myeloid Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Guenther Koehne, MD, PhD, Miami Cancer Institute

Podcasts

Therapeutic Advances and Considerations for Treatment Selection in High-Risk AML

04/13/2022

Guenther Koehne, MD, PhD, interviews Richard Stone, MD; Robert Soiffer, MD; and Siddhartha Mukherjee, MD, on recent therapeutic advances for hematologic malignancies with a focus on considerations for treatment selection in high-risk AML.

Guenther Koehne, MD, PhD,...

04/13/2022

Oncology

Videos

Guenther Koehne, MD, PhD, Shares Details on New FDA-Approved Trials in AML

03/29/2022

Guenther Koehne, MD, PhD, highlights 2 new FDA-approved clinical trials, including a pilot study on CPX351 plus midostaurin followed by alloHSCT for AML and a phase 1 dose trial of lymphocyte infusions following CD34-selected alloHSCT for the...

Guenther Koehne, MD, PhD,...

03/29/2022

Oncology

Videos

Dr Uy Reviews Low-Dose CPX-351 Plus Venetoclax for AML

03/09/2022

Geoffrey L. Uy, MD, reviews the safety and efficacy results from a phase 1b study on lower-dose CPX-351 plus venetoclax as a first-line treatment for patients with AML who are unfit for intensive chemotherapy, presented at ASH 2021.

Geoffrey L. Uy, MD, reviews the...

03/09/2022

Oncology

Videos

GVHD Outcomes of Busulfan Plus Fludarabine for Older Patients With Hematologic Malignancies

03/03/2022

Uday R Popat, MD, overviews the long-term disease outcomes from a phase 2 prospective clinical trial on myeloablative fractionated busulfan with fludarabine in older patients with hematologic malignancies.

Uday R Popat, MD, overviews the...

03/03/2022

Oncology

Videos

Orca-T Demonstrates Reduced Instances of GVHD for Hematologic Malignancies

01/24/2022

Dr Meyer on how Orca-T, an investigational cell therapy, led to high GVHD- and relapse-free survival following myeloablative conditioning for hematologic malignancies, presented at ASH 2021.

Dr Meyer on how Orca-T, an...

01/24/2022

Oncology

Videos

Dr Jamy Highlights HMAs Plus Venetoclax for Patients With R/R AML

01/18/2022

Omer Hassan Jamy, MD, highlights a retrospective study on HMAs plus venetoclax versus intensive chemotherapy for patients with R/R AML. These data were presented at the 2021 ASH Annual Meeting.

Omer Hassan Jamy, MD, highlights...

01/18/2022

Oncology

Videos

Dr Lee Highlights the Treatment Landscape for Patients With MDS, AML

11/29/2021

Sangmin Lee, MD, highlights the current treatment landscape for patients with MDS, including novel therapies that are in development in combination with hypomethylating agents.

Sangmin Lee, MD, highlights the...

11/29/2021

Oncology

Podcasts

Tapan Kadia, MD, Highlights Venetoclax Plus Chemotherapy for AML, MDS

11/11/2021

Tapan M. Kadia, MD, highlights a phase 2 trial on venetoclax plus intensive chemotherapy in patients with newly diagnosed AML or MDS.

Tapan M. Kadia, MD, highlights a...

11/11/2021

Oncology

Videos

Triplet Combo Highly Active in Relapsed/Refractory FLT3-Mutated AML

11/03/2021

Musa Yilmaz, MD, discusses a highly active triplet combination for patients with FLT3-ITD mutated AML. These data were presented at the 2021 ASCO Annual Meeting.

Musa Yilmaz, MD, discusses a...

11/03/2021

Oncology

Videos

Dr Azab Highlights Nanoparticle T Cell Engagers for Patients With AML

10/22/2021

Kareem Azab, PhD, Washington University, highlights nanoparticle T cell engagers for the treatment of patients with AML.

Kareem Azab, PhD, Washington...

10/22/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology